DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for metachromatic leukodystrophy — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMetachromatic leukodystrophy maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for metachromatic leukodystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
arylsulfatase A (ARSA) — ARSA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sulfooxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1E2S · 2.35 Å · ligand N,4-DIHYDROXY-N-OXO-3-(SULFOOXY)BENZENAMINIUM (CSN). Experimental structure, not a prediction.
What the evidence adds up to
Metachromatic leukodystrophy is a lysosomal storage disorder caused by deficiency of arylsulphatase A, leading to intralysosomal storage of cerebroside sulphate and progressive demyelination of the nervous system. Patients usually die within a few years from onset of symptoms. The molecular basis for the different clinical forms (late-infantile, juvenile, adult) was unknown at the time of the 1990 review. A substantial arylsulphatase A deficiency can also occur in healthy individuals, a phenotype termed pseudodeficiency, for which two concurrent mutations were identified and a rapid detection assay developed. The disease can also be caused by deficiency of an arylsulphatase A activator protein (sphingolipid activator protein B); the cDNA for its precursor had been isolated and a mutant cDNA from one patient analysed.
Bone marrow transplantation had been tried in several patients by 1990, with evidence that it might slow or halt progression, but no final conclusion on its suitability as therapy could be drawn. By 2008, bone marrow transplantation was described as a therapeutic option available for metachromatic leukodystrophy, and a new MRI scoring system was established to describe white matter changes over time, building on previous work in adrenoleukodystrophy. This score was not intended for initial diagnosis but for reliably tracking disease progression in the context of treatment.
A 2019 supplementary table listed ongoing clinical trials on metachromatic leukodystrophy registered on ClinicalTrials.gov, including trials of haematopoietic stem cell-directed gene therapy, bone marrow transplant, peripheral blood stem cell transplant, and umbilical cord blood transplant. No numerical outcomes (survival, response rates, sample sizes) from these trials were provided in the abstract. What remains missing is published evidence from controlled trials with sufficient patient numbers to determine whether any of these interventions reliably alter the course of the disease, and how to stratify patients by disease form or genetic subtype to identify who might benefit.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Inherited Metabolic Disease · 1990 · 12 citations
Advances in the molecular genetics of metachromatic leukodystrophy
AbstractMetachromatic leukodystrophy is a lysosomal storage disorder caused by the deficiency of arylsulphatase A (EC 3.1.6.1). This results in the intralysosomal storage of cerebroside sulphate, which leads to a progressive demyelination of the nervous system. The patients usually die within a few years from the onset of symptoms. Clinically, there are different forms of the disease and the molecular basis for this heterogeneity is unknown. The gene for arylsulphatase A has recently been cloned and provides a necessary tool for the exact description of the molecular defects occurring in the different forms of metachromatic leukodystrophy. Metachromatic leukodystrophy can also be caused by the deficiency of an arylsulphatase A activator protein (sphingolipid activator protein B). The cDNA for the precursor of this protein has been isolated and a mutant cDNA of one patient has been analysed. A substantial arylsulphatase A deficiency can also occur in healthy individuals, a phenotype termed pseudodeficiency. Two concurrent mutations have been identified in this low arylsulphatase A activity allele. This permitted the development of a rapid assay which allows the detection of the pseudodeficiency allele. Bone marrow transplantation has been tried in several metachromatic leukodystrophy patients and there is evidence that this treatment might slow or even halt the progression of the disease. A final conclusion as to whether bone marrow transplantation is a suitable therapy for metachromatic leukodystrophy cannot be drawn yet.
A new score for assessing white matter changes in metachromatic leukodystrophy
AbstractMetachromatic leukodystrophy (MLD) is a neurodegenerative disorder interfering with sulfatide degradation. A late-infantile form can be distinguished from juvenile and adult forms. The aim of this project was the establishment of an objective score for describing changes in MR-imaging on the basis of previous attempts to describe such changes in adrenoleukodystrophy (Loes, 2003). It is not aimed at aiding in the initial diagnostic but should rather reliably describe the changes over time, as now, with bone marrow transplantation, a therapeutic option is available.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
